+44 (0)1382 385766
14-3-3–phosphoprotein signaling networks in health and disease
Our recent work on how insulin regulates the 14-3-3-interacting phosphoproteome has given unexpected insights into the evolution of cell signaling networks, which in turn provide a new conceptual framework for elucidating how signaling networks are dysregulated in diabetes, cancer and neurological disorders.
The 14-3-3–interactome mediates whole body responses to insulin
People with diabetes can suffer serious complications such as kidney and heart disease, cognitive problems, and blindness. The prevailing view is that these diabetic syndromes are secondary consequences of glucose toxicity due to defective insulin control of glucose homeostasis. However, our recent findings suggest a rethink, as follows:
We discovered that insulin stimulates the rapid phosphorylation of hundreds of specific proteins in most tissues and organs tested. The resulting phosphoproteins dock into C-shaped proteins named 14-3-3s, and can then play specialized roles in mediating diverse physiological responses to insulin: for example, certain phosphoprotein–14-3-3 complexes coordinate the uptake of glucose into skeletal muscle, others gear up the kidneys for increased urine production, and alter cardiac metabolism and contractility to regulate tissue blood flow. Interestingly, the insulin-regulated kidney and cardiac proteins that we have identified include several with known genetic links to renal and heart failure, respectively. These findings suggest that diabetic kidney and cardiac diseases may stem from genetic or biochemical faults in insulin control of regulatory proteins within these organs. Glucose need not always be the middleman.
We also discovered that insulin in the bloodstream triggers rapid changes in brain proteins. This was surprising because the brain is protected by the blood-brain barrier, which prevents bloodstream insulin from entering the brain. Intriguingly, in contrast to kidneys and heart where insulin increases interactions between phosphoproteins and 14-3-3s, many brain phosphoproteins lose phosphates and can no longer dock onto 14-3-3s when blood insulin levels rise after feeding. Our working hypothesis is that insulin transmits an unknown signal across the blood-brain barrier that may decrease levels of the neurotransmitter dopamine, which in turn causes the widespread brain changes that we observe.
We are investigating these brain changes in molecular detail, including how systemic insulin and 14-3-3s control a set of brain (phospho)proteins that work together to alter neuronal cell morphology. Another brain protein is translocated in and out of the cell nucleus depending on whether or not it is phosphorylated and docked onto a 14-3-3 protein. In future, we wish to collaborate with behavioural neuroscientists to define how such molecular events contribute to changes in emotions, motivation and behaviour when we eat. We are also keen to investigate whether defects in insulin control of brain proteins explains why certain people with diabetes are at risk of cognitive decline and Alzheimer’s disease.
In summary, by working out the precise mechanisms by which insulin and 14-3-3 proteins influence the inner workings of the heart, brain and other organs we hope and expect to bring new understanding of the diverse manifestations of diabetes. Glucose control is only part of the picture.
See Figure 1 below: Example of an insulin-regulated 14-3-3–phosphoprotein interaction
Left: ZNRF2 is an E3 ubiquitin ligase with an N-terminal myristoyl moiety that interacts with intracellular membranes. On membranes, the RING domain of ZßNRF2 participates in ubiquitylation of certain ion pumps, thereby influencing cellular ion balance and nutrient sensing.
Right: In response to insulin, IGF1 and other stimuli, ZNRF2 is phosphorylated by various kinases, and phosphoSer19 and phosphoSer82 dock onto a 14-3-3 dimer. Our data indicate that 14-3-3 binding causes a disorder-to-order transition in ZNRF2, creating a pocket for the N-myristoyl group to tuck into. Therefore, insulin and IGF1 cause the protein to dissociate from membranes into the cytosol.
An evolutionary leap in vertebrate 14-3-3–phosphoprotein signaling networks
Remarkably, around 90% of the insulin-regulated 14-3-3-binding phosphoproteins that we have identified are ‘ohnologues’, which means that they belong to protein families that were generated by two rounds of whole genome duplication (2R-WGD) at the evolutionary origin of the vertebrates. These 14-3-3-regulated ohnologue phosphoproteins include many signaling proteins such as protein kinases, regulators of small GTPases, ubiquitin ligases, cytoskeletal regulators, and transcription factors. This means that a boost to the 14-3-3–interactome, and cell signaling in general, was fundamental to evolution of the vertebrate animals, which has all sorts of practical and conceptual implications.
Based on our biochemical data, we propose that the simple linear signaling pathways in the invertebrates were converted via the 2R-WGD into multi-stranded parallelised networks. Different combinations of sister ohnologues in these networks are co-regulated under different condition. For example, one set of ohnologues is phosphorylated and captured by 14-3-3s in cells stimulated by insulin, whereas their sister ohnologues have evolved 14-3-3-binding phosphosites that are phosphorylated when cells are energy stressed, or stimulated by adrenalin and growth factors. In principle, such networks can respond to a wide array of environmental, sensory and hormonal stimuli and integrate them to generate phenotypic variety in cell types and behaviours.
Patterns are also being discerned in how the vertebrate signaling networks are reconfigured in human cancers and neurological conditions. For example Figure 2 shows a hypothesis generated from our recent analysis of mutations in multiple cancer genomes.
See Figure 2 below: Evolution of cellular signaling networks in the vertebrates, and hypothesis that in many cancers, certain pathways through these signaling networks are ‘shut down’, while others are ‘jammed open’
Together, these recent findings have opened up exciting new projects in my lab, combining biochemical dissections of regulatory mechanisms, disease bioinformatics and evolutionary approaches. It is fascinating to unpick how ancient genomic events impact on complexity, variety and disease in modern life.
- Level 3 BS32006 Cell Signalling
- Level 3 BS32005 Developmental Biology
- Level 4 BS42013 Advanced Cell Signalling
- Tutor for DJ31001 Art, Science and Visual Thinking
- Senior Honours project supervisor
Diabetes and cancer as disorders of 'signal multiplexing' in the vertebrate animals
|Fellow of the Royal Society of Biology||2012|
|Brian Cox Award: Public Engagement / Senior Researcher||2011|
I am available for media commentary on my research.
Contact Corporate Communications for media enquiries.
Areas of Expertise